Solaris Pharma
Solaris Pharma Corporation is a leading specialty pharmaceutical company committed to the identifying, developing, and marketing of high-quality, complex, generic and specialty pharmaceutical products. The company employs an experienced R&D and management team focused on right-first-time development while maintaining the highest quality standards. It aims to be a pacesetter in the niche pharmaceutical market by developing a broad portfolio of complex generic and specialty pharmaceutical products, providing patients with high-quality, affordable, effective, and value-added options. Solaris Pharma's products are challenging to develop and manufacture, offering a niche market opportunity due to their scientific and regulatory hurdles.
Industries
Nr. of Employees
small (1-50)
Solaris Pharma
1031 Route 202/206, Suite G-200, New Jersey 08807
Products
Tazarotene Gel, 0.1%
Topical tazarotene gel formulation provided in 30 g and 100 g presentations.
Tazarotene Gel, 0.05%
Topical tazarotene gel formulation provided in 30 g and 100 g presentations.
Clindamycin Phosphate and Tretinoin Gel, 1.2%/0.025%
Combination topical gel product available in 30 g and 60 g sizes.
Metronidazole Vaginal Gel, 0.75%
Vaginal gel formulation provided in 70 g size for gynecologic indication.
Clindamycin Phosphate Gel USP, 1% (Once‑A‑Day)
Topical clindamycin gel in a once-daily strength and presentation (75 mL).
Clindamycin Phosphate Gel USP, 1% (Twice‑A‑Day)
Topical clindamycin gel available in 30 g and 60 g packages for twice-daily use.
Tazarotene Gel, 0.1%
Topical tazarotene gel formulation provided in 30 g and 100 g presentations.
Tazarotene Gel, 0.05%
Topical tazarotene gel formulation provided in 30 g and 100 g presentations.
Clindamycin Phosphate and Tretinoin Gel, 1.2%/0.025%
Combination topical gel product available in 30 g and 60 g sizes.
Metronidazole Vaginal Gel, 0.75%
Vaginal gel formulation provided in 70 g size for gynecologic indication.
Clindamycin Phosphate Gel USP, 1% (Once‑A‑Day)
Topical clindamycin gel in a once-daily strength and presentation (75 mL).
Clindamycin Phosphate Gel USP, 1% (Twice‑A‑Day)
Topical clindamycin gel available in 30 g and 60 g packages for twice-daily use.
Services
Engagements for partnerships, licensing and alliance opportunities to collaborate on product development or commercialization; contact via provided business development email.
Collaborative regulatory strategy and product development support for complex generic and specialty products.
Engagements for partnerships, licensing and alliance opportunities to collaborate on product development or commercialization; contact via provided business development email.
Collaborative regulatory strategy and product development support for complex generic and specialty products.
Expertise Areas
- Complex generic product development
- Formulation development for topical, sterile and oral dosage forms
- Regulatory strategy and FDA submissions
- Analytical chemistry and QC testing
Key Technologies
- Topical gel formulation
- Sterile product development (solutions and ophthalmics)
- Tablet formulation
- Stability testing protocols